Protective and restorative effects of magnolol on neurotoxicity in mice with 6-hydroxydopamine-induced hemiparkinsonism

Neurodegenerative Diseases

Volumn 8, Issue 5, 2011, Pages 364-374

  Chen, Hwei Hsien ^a   Lin, Shiau Chin ^a   Chan, Ming Huan ^a  

^a TZU CHI UNIVERSITY   (Taiwan)

Author keywords

6 Hydroxydopamine; Apomorphine; Magnolol; Parkinson's disease; Tyrosine hydroxylase

Indexed keywords

APOMORPHINE; MAGNOLOL; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR CHANGE; CIRCLING BEHAVIOR; CONTROLLED STUDY; CORPUS STRIATUM; DOSE RESPONSE; DRUG DOSE COMPARISON; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; BIPHENYL COMPOUNDS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; LIGNANS; MALE; MICE; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; PARKINSONIAN DISORDERS; TYROSINE 3-MONOOXYGENASE;

EID: 79958811068     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000323872     Document Type: Article

References (36)

1. Singh M, Arseneault M, Sanderson T, Murthy V, Ramassamy C: Challenges for research on polyphenols from foods in Alzheimer's disease: bioavailability, metabolism, and cellular and molecular mechanisms. J Agric Food Chem 2008;56:4855-4873. (Pubitemid 352039080)
2. Ramassamy C: Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: a review of their intracellular targets. Eur J Pharmacol 2006;545:51-64.
3. Fujita M, Itokawa H, Sashida Y: Studies on the components of Magnolia obovata Thunb. 3. Occurrence of magnolol and hõnokiol in M. obovata and other allied plants (in Japanese). Yakugaku Zasshi 1973;93:429-434.
4. Maruyama Y, Kuribara H, Morita M, Yuzurihara M, Weintraub ST: Identification of magnolol and honokiol as anxiolytic agents in extracts of saiboku-to, an oriental herbal medicine. J Nat Prod 1998;61:135-138. (Pubitemid 28086994)
5. Irie T, Miyamoto E, Kitagawa K, Maruyama Y, Inoue K, Inagaki C: An anxiolytic agent, dihydrohonokiol-B, inhibits ammonia-induced increases in the intracellular Cl(-) of cultured rat hippocampal neurons via GABA(c) receptors. Neurosci Lett 2001;312:121-123. (Pubitemid 32938243)
6. Chang CK, Chang CP, Liu SY, Lin MT: Oxidative stress and ischemic injuries in heat stroke. Prog Brain Res 2007;162:525-546.
7. Lin YR, Chen HH, Ko CH, Chan MH: Neuroprotective activity of honokiol and magnolol in cerebellar granule cell damage. Eur J Pharmacol 2006;537:64-69.
8. Lin YR, Chen HH, Ko CH, Chan MH: Effects of honokiol and magnolol on acute and inflammatory pain models in mice. Life Sci 2007;81:1071-1078.
9. Lin YR, Chen HH, Ko CH, Chan MH: Differential inhibitory effects of honokiol and magnolol on excitatory amino acid-evoked cation signals and NMDA-induced seizures. Neuropharmacology 2005;49:542-550.
10. Lin YR, Chen HH, Lin YC, Ko CH, Chan MH: Antinociceptive actions of honokiol and magnolol on glutamatergic and inflammatory pain. J Biomed Sci 2009;16:94.
11. Armstrong RJ, Barker RA: Neurodegeneration: a failure of neuroregeneration? Lancet 2001;358:1174-1176.
12. Jenner P, Olanow CW: The pathogenesis of cell death in Parkinson's disease. Neurology 2006;66:S24-S36.
13. Clarke CE: Neuroprotection and pharmacotherapy for motor symptoms in Parkinson's disease. Lancet Neurol 2004;3:466-474.
14. Bonsi P, Cuomo D, Picconi B, Sciamanna G, Tscherter A, Tolu M, et al: Striatal metabotropic glutamate receptors as a target for pharmacotherapy in Parkinson's disease. Amino Acids 2007;32:189-195. (Pubitemid 46198742)
15. Walker RH, Koch RJ, Sweeney JE, Moore C, Meshul CK: Effects of subthalamic nucleus lesions and stimulation upon glutamate levels in the dopamine-depleted rat striatum. Neuroreport 2009;20:770-775.
16. Verkhratsky A, Kirchhoff F: Glutamate-mediated neuronal-glial transmission. J Anat 2007;210:651-660. (Pubitemid 46851000)
17. Brundin P, Nilsson OG, Strecker RE, Lindvall O, Astedt B, Bjorklund A: Behavioural effects of human fetal dopamine neurons grafted in a rat model of Parkinson's disease. Exp Brain Res 1986;65:235-240. (Pubitemid 17004013)
18. Cunningham LA, Su C: Astrocyte delivery of glial cell line-derived neurotrophic factor in a mouse model of Parkinson's disease. Exp Neurol 2002;174:230-242. (Pubitemid 34295786)
19. Schober A: Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res 2004;318:215-224.
20. Tirmenstein MA, Hu CX, Scicchitano MS, Narayanan PK, McFarland DC, Thomas HC, et al: Effects of 6-hydroxydopamine on mitochondrial function and glutathione status in SH-SY5Y human neuroblastoma cells. Toxicol In Vitro 2005;19:471-479.
21. Hara H, Ohta M, Ohta K, Kuno S, Adachi T: Increase of antioxidative potential by tertbutylhydroquinone protects against cell death associated with 6-hydroxydopamine-induced oxidative stress in neuroblastoma SH-SY5Y cells. Brain Res Mol Brain Res 2003;119:125-131. (Pubitemid 37415085)
22. Borlongan CV, Sanberg PR: Elevated body swing test: a new behavioral parameter for rats with 6-hydroxydopamine-induced hemiparkinsonism. J Neurosci 1995;15:5372-5378.
23. Soto-Otero R, Mendez-Alvarez E, Hermida-Ameijeiras A, Munoz-Patino AM, Labandeira-Garcia JL: Autoxidation and neurotoxicity of 6-hydroxydopamine in the presence of some antioxidants: potential implication in relation to the pathogenesis of Parkinson's disease. J Neurochem 2000;74:1605-1612. (Pubitemid 30163982)
24. Iancu R, Mohapel P, Brundin P, Paul G: Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice. Behav Brain Res 2005;162:1-10. (Pubitemid 40726275)
25. Liang Q, Smith AD, Pan S, Tyurin VA, Kagan VE, Hastings TG, et al: Neuroprotective effects of TEMPOL in central and peripheral nervous system models of Parkinson's disease. Biochem Pharmacol 2005;70:1371-1381. (Pubitemid 41383473)
26. Lee YM, Hsiao G, Chen HR, Chen YC, Sheu JR, Yen MH: Magnolol reduces myocardial ischemia/reperfusion injury via neutrophil inhibition in rats. Eur J Pharmacol 2001;422:159-167. (Pubitemid 32595587)
27. Chang CP, Hsu YC, Lin MT: Magnolol protects against cerebral ischaemic injury of rat heatstroke. Clin Exp Pharmacol Physiol 2003;30:387-392. (Pubitemid 36713997)
28. Liou KT, Shen YC, Chen CF, Tsao CM, Tsai SK: The anti-inflammatory effect of honokiol on neutrophils: mechanisms in the inhibition of reactive oxygen species production. Eur J Pharmacol 2003;475:19-27.
29. Jin F, Wu Q, Lu YF, Gong QH, Shi JS: Neuroprotective effect of resveratrol on 6-OHDAinduced Parkinson's disease in rats. Eur J Pharmacol 2008;600:78-82.
30. Khan MM, Ahmad A, Ishrat T, Khan MB, Hoda MN, Raza SS, et al: Resveratrol attenuates 6-hydroxydopamine-induced oxidative damage and dopamine depletion in rat model of Parkinson's disease. Brain Res 2010;1328:139-151.
31. Spooren WP, Waldmeier P, Gentsch C: The effect of a subchronic post-lesion treatment with (-)-deprenyl on the sensitivity of 6-OHDA-lesioned rats to apomorphine and d-amphetamine. J Neural Transm 1999;106:825-833. (Pubitemid 29516052)
32. Shim JS, Kim HG, Ju MS, Choi JG, Jeong SY, Oh MS: Effects of the hook of Uncaria rhynchophylla on neurotoxicity in the 6-hydroxydopamine model of Parkinson's disease. J Ethnopharmacol 2009;126:361-365.
33. Kong LD, Cheng CH, Tan RX: Inhibition of MAO A and B by some plant-derived alkaloids, phenols and anthraquinones. J Ethnopharmacol 2004;91:351-355. (Pubitemid 38561134)
34. Schmidt WJ, Bubser M, Hauber W: Behavioural pharmacology of glutamate in the basal ganglia. J Neural Transm Suppl 1992;38:65-89. (Pubitemid 23026847)
35. Pollack AE, Haisley EC: NMDA glutamate receptor stimulation is required for the expression of D2 dopamine mediated responses in apomorphine primed 6-hydroxydopamine lesioned rats. Brain Res 2001;897:213-216. (Pubitemid 32244374)
36. Porras A, Mora F: Dopamine-glutamate-GABA interactions and ageing: studies in the striatum of the conscious rat. Eur J Neurosci 1995;7:2183-2188.